<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013

    PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

    Biodesix Closes Series D Financing - April 2013

    April 12, 2013

    Biodesix closed on $8.8 million in a follow-on sale of its Series D preferred shares.

    Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    April 2, 2013

    Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.

    Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

    June 3, 2013

    Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.

    VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients With Lung Cancer

    February 20, 2013

    Journal of Thoracic Oncology Study: VerStrat provides oncologists with more information to personalize therapy for their patients.

    Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    March 18, 2013

    Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.

    Biodesix to Present at World CDx

    November 15, 2013

    Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.

    Biodesix to Announce Results of VeriStrat® Biomarker Study

    May 21, 2013

    Biodesix presents data on VeriStrat biomarker study at ASCO 2013

    Biodesix Secures Medicare Coverage for VeriStrat Test

    June 20, 2013

    Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.

    Biodesix Closes Series E Financing

    December 3, 2013

    Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.